FindTrial
Sign In

Effect of Yangjing Zhongyu Decoction on Clinical Pregnancy Rate in Ovulation Induction Cycles for Patients with Polycystic Ovary Syndrome: A Multicenter, Randomized, Controlled Clinical Trial

Effect of Yangjing Zhongyu Decoction on Clinical Pregnancy Rate in Ovulation Induction Cycles for Patients with Polycystic Ovary Syndrome: A Multicenter, Randomized, Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121760
Enrollment
Unknown
Registered
2026-04-02
Start date
2026-04-05
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Chinese Medicine Group:Yangjing Zhongyu Decoction Granules (Rehmannia glutinosa 30g, Angelica sinensis 15g, Stir-fried Peony root 15g, Cornus officinalis 15g), twice daily, one packet each time, from
Placebo Chinese Medicine Group:Placebo Granules (containing 5% original herb, 10% bitter gourd granules, 5% Scutellaria barbata granules, 0.2% tartrazine, 20% gelatin, 15% soluble starch, 5% flour, 39

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to 39 Years

Inclusion criteria

Inclusion criteria: 1. Met the Rotterdam diagnostic criteria for PCOS; 2. Poor embryo quality in the first IVF/ICSI cycle, with failure to conceive after both fresh and frozen-thawed embryo transfers, planning to restart IVF ovarian stimulation; 3. Age < 40 years, undergoing ovarian stimulation with the antagonist protocol; 4. Patients agreed to receive the treatment of this group and signed informed consent forms.

Exclusion criteria

Exclusion criteria: 1. PGT cycle; recurrent miscarriage; genital tract malformations; intrauterine adhesions; thin endometrium (<7mm); submucosal uterine fibroids or intramural fibroids affecting cavity morphology; moderate-to-severe endometriosis; autoimmune diseases; chromosomal abnormalities in either partner. 2. Hydrosalpinx without prior ligation or salpingectomy. 3. Received TCM therapies (e.g., acupuncture) within the past 3 months. 4. Patients undergoing testicular sperm extraction (TESE) or micro-TESE. 5. Severe primary diseases of the heart, liver, lungs, kidneys, brain, or hematologic system; or psychiatric disorders. 6. Endocrine disorders caused by other primary diseases, such as adrenal hyperplasia, hyperprolactinemia, thyroid diseases, or tumors. 7. Severe adverse reactions to study drugs (Gn, GnRH antagonists, Chinese herbal medicine, etc.). 8. Unwillingness to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rate;—

Secondary

MeasureTime frame
Number of oocytes retrieved;Two-pronucleus (2PN) fertilization rate;Blastocyst formation rate;Number of usable embryos;High-quality embryo rate;Persistent pregnancy rate;Live birth rate;Early miscarriage rate;Late miscarriage rate;—

Countries

China

Contacts

Public ContactJin Lei

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

ljin@tjh.tjmu.edu.cn+86 137 0710 5776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026